The use of 2 monoclonal antibodies (MAbs), P1D9 and P2D4, which recognize different fowlpox virus (FPV) antigens, for the identification and characterization of FPV strains was evaluated. Initially, the MAbs were used in conjunction with a dot blot assay that enabled FPV to be differentiated from the avian herpesvirus, infectious laryngotracheitis virus. Confirmation of the specificity of these MAbs was provided by the demonstration that only FPV antigens were recognized by a combination of both antibodies when used for immunoblotting proteins contained in various avipoxviruses. Later, an antigenic characterization of 11 FPV field isolates, 6 FPV vaccine strains, and 3 pigeonpox virus vaccines was performed by Western blotting with the individual MAbs. Whereas MAb P2D4 consistently recognized a protein with an apparent molecular weight of 60 kD, there was variability in the size of the antigen that was immunoreactive with the other MAb. For example, MAb P1D9 recognized an antigen of apparent molecular weight of 46 kD in all vaccine strains except 2 of FPV origin. In these exceptions, either only a 39-kD or both a 42-and 46-kD protein were immunoreactive. As for the field isolates, a 39-kD antigen was recognized in 8 of them, whereas a 42-kD antigen was detected in the remaining 3. Therefore, the more extensive immunoblotting technique may facilitate FPV strain differentiation, whereas routine diagnosis of fowlpox could be accomplished by using the MAb-based dot blot assay.
Fowlpox is a common viral disease of poultry and is manifested in two forms: cutaneous and diphtheritic. 10 Although both types can occur in the same bird, the latter is of more concern because it causes significant mortality and economic losses in affected flocks. Moreover, the diphtheritic tracheal lesions are often confused with those caused by the avian herpesvirus, infectious laryngotracheitis virus (ILTV). Currently, diagnosis of fowlpox is based on clinical signs as well as the isolation and identification of the causative agent, fowlpox virus (FPV). Lesions on the unfeathered skin areas, especially the comb and wattles, are characteristic of the disease and fowlpox may be confirmed by microscopic detection of eosinophilic cytoplasmic inclusions in hematoxylin and eosin-stained sections of such damaged areas. FPV can be isolated from skin, oral, or tracheal lesions by inoculation of this affected tissue onto the chorioallantoic membranes (CAM) of embryonating chicken eggs. A positive histopathological evaluation of the resultant pocks is based on the presence of cytoplasmic inclusions. Electron microscopic examination of sectioned pocks will reveal that 300-450 nm brick-to oval-shaped virus particles are in the cells' cytoplasm. FPV can also be detected in tissues by using immunofluorescence, ELISA, or polymerase chain reaction. 11 Although an immunodiffusion test is often used for detection of FPV antigens, it is not sensitive, has variable specificity, and requires a high level of precipitating antibodies in the sera. 9 Vaccines of fowlpox and pigeonpox virus origin have been used for prevention of the disease for the past several decades by the poultry industry. Despite regular vaccinations, outbreaks of fowlpox have continued to occur suggesting antigenic variation among FPV strains. 2, 8 Therefore, differentiation of vaccine strains from field isolates has become important. In this regard, the FPV genome has a capability of producing more than 200 proteins, of which some are immunogenic. Presumably, a few of these antigens have epitopes conserved among various avipoxviruses resulting in cross-reactivity being observed when anti-FPV polyclonal antiserum was used. 3 However, even under these conditions, some antigenic heterogeneity among FPV vaccines and field isolates has been detected. 5 To possibly enhance the specificity of immunological tests and, more importantly, provide a means of differentiating between commercial FPV vaccines and naturally occurring viruses, we generated monoclonal antibodies (MAbs) against two distinct FPV proteins. 7 In the current study, the feasibility of using these 2 MAbs to identify and characterize FPV strains as well as to differentiate them from other avipoxviruses was evaluated. Initially for this purpose, a simple immuno-dot blot assay was developed for the detection of FPV antigens in lesion samples. Subsequently, immunoblotting was used to exploit the variability in the size of the virus-encoded protein recognized by one of the MAbs. 7 As a result, although all the examined FPV strains produced both antigens, they still could be subdivided into four groups.
FPV field and vaccine strains ( Table 1) were propagated in either CAM or QT-35 cell monolayers as described previously. 5 The FPV challenge strain was obtained from National Veterinary Science Laboratories. a For comparison, genetically and antigenically different avipox viruses were included in the study. Quail pox virus 3 was grown in QT-35 cells. ILTV and the pox viruses isolated from Hawaiian birds (Apapane and Alala) 12 were propagated in the LMH cell line. 4 Pox viruses isolated from condor and cardinal (Kim and Tripathy, unpublished) were grown CAMs.
Lesions produced on the combs of chickens infected with FPV strain OK-98 7 and pocks on virus-infected CAMs were triturated with allundum b in a mortar and pestle. The suspensions were clarified by centrifugation at 500 ϫ g and 25 C for 10 minutes and the resulting supernatants were combined with an equal volume of extraction buffer (20 mM Tris, pH 8.0, 20 mM KCl, 10% SDS, 2% sodium desoxycholate, 0.5% ␤-mercaptoetha- nol). After the addition of proteolytic inhibitor cocktail c to a final concentration of 1%, the lysates were rotated for 2 hours at 25 C and then centrifuged at 1000 ϫ g at 25 C for 10 minutes. Supernatants were used as a source of antigens for both dot blots and immunoblots. Regions of uninfected CAMs and comb tissue from uninfected chickens were processed similarly to obtain cellular proteins. Lyophilized FPV and pigeonpox virus vaccines were directly resuspended in extraction buffer and then subsequently treated as described above. Lysates of virus-infected and uninfected cell cultures were prepared as previously described. 7 The protein concentration in each preparation was determined by using the Bio-Rad protein dye system d and then adjusted to 5 mg/ml with extraction buffer before use in the immunological assays.
For the dot blot, proteins were applied to a PVDF membrane d by using a Minifold blotting apparatus. e One hundred microliters of each sample were added to an individual well, which was then washed 3 times with phosphate-buffered saline (PBS). For immunoblotting, the antigens were resolved by SDS-PAGE and transferred to a PVDF membrane d as described previously. 7 PVDF membranes were processed for the detection of antigens as described below. First, nonspecific binding sites on the membranes were blocked during incubation for 1 hour at 37 C in PBS (pH 7.4) containing 3% bovine serum albumin (BSA). Afterwards, the membranes were washed three times for 5 minutes in PBS containing 0.05% Tween 20 (PBST) and then exposed for 1 hour at 37 C to either tissue culture supernatants from hybridomas producing MAb or chicken anti-FPV MN-97 polyclonal antibody that had been diluted 1:2,000 in PBS containing 1% BSA (BPBS). After three 5-minute washes in PBST, the membranes were incubated for 1 hour at 37 C with either alkaline phosphatase-conjugated goat antimouse IgG d diluted 1:3,000 in BPBS or with alkaline phosphatase-conjugated goat anti-chicken IgG f diluted 1:2,500 in BPBS. After an additional three 5-minute washes in PBST, bound secondary antibodies were detected with the Alkaline Phosphatase Substrate Kit. d The molecular weights of the identified proteins were determined on the basis of their mobilities relative to that of precision prestained SDS-PAGE standards. d MAbs P1D9 and P2D4 as well as chicken polyclonal anti-FPV serum (raised against the MN-97 field strain) were previously generated in our laboratory. 7 When the specificity of MAbs P1D9 and P2D4 in the dot blot assay was evaluated, both antibodies only reacted with lysates of FPV-infected cells and not with those prepared from uninfected or ILTV-infected cells (Fig. 1) . Similar positive results were obtained regardless of whether the source of virus protein was FPV field strain-or vaccine strain-infected CAMs and cultured cells, manufacturer-supplied, lyophilized FPV vaccines or skin lesions in chickens infected with FPV MN-97 or NE-92 (data not shown). Interestingly, a 2-fold greater sensitivity was obtained when using MAb P1D9 in comparison with MAb P2D4 (Fig. 1) . Although the reason for this enhancement is unknown, one possibility is that there may be a relatively greater intracellular quantity of the FPV antigen recognized by MAb P1D9 as compared with that reacting with MAb P2D4.
To further examine the specificity of the 2 anti-FPV MAbs, their reactivities with lysates prepared from cells infected with various avipox viruses were assessed. In this case, the proteins in each preparation were electrophoretically separated before exposure to a combination of both MAbs so that the size(s) of any cross-reacting antigens could be compared. Although 2 proteins were detected in the lysate of FPV-infected cells, antibody reactivity with any of the other preparations was not observed ( Fig. 2A) . In contrast, a variety of different-sized proteins in these lysates were recognized by the polyclonal anti-FPV serum (Fig.  2B) . Of special note are the cross-reacting, approximately 30-kD antigen common only to the 2 pox viruses from Hawaiian birds and the approximately 16-kD antigen conserved in all of the avipoxviruses except FPV. Some proteins from uninfected and ILTVinfected cells also reacted with the antibodies. This recognition, as well as that of related poxviruses by polyclonal serum, underscores the importance of using MAbs such as the FPV-specific P1D9 and P2D4 for diagnostic purposes.
Because the above-mentioned dot blot assay is only practical for demonstrating the presence of either 1 or 2 common FPV proteins, the use of the MAbs in conjunction with Western blotting for the differentiation of FPV and pigeonpox virus strains was evaluated. As previously observed, 7 MAb P2D4 consistently reacted with an FPV and pigeonpox virus protein having an invariant approximate molecular weight of 60 kD ( Table 1 ). It should be noted that previously the size of this antigen was erroneously calculated to be 80 kD. 7 However, upon reevaluation, this immunoreactive protein was found to be approximately 60 kD. When MAb P2D4 was replaced by the variable-sized antigen-recognizing MAb P1D9, 4 categories of FPV isolates were identified on the basis of the approximate molecular weight of the detected protein ( Fig. 3 ; Table  1 ). Whereas all field strains expressed either a 39-or 42-kD protein, only 1 vaccine was associated with the 39-kD antigen. A second vaccine did have the 42-kD protein and also contained an additional 46-kD antigen. All the remaining FPV vaccines as well as the 3 pigeonpox virus ones appeared to encode only the largest (46 kD) size of this immunoreactive protein.
It is interesting to note that all of the FPV field strains express 1 of the 2 smaller forms of the protein recognized by MAb P1D9. Unfortunately, the ability of Chick-n-Pox TC strain to do the same precludes using the size of this antigen to distinguish between FPV field and vaccine strains isolated during outbreaks of the associated disease. The existence of the dual protein-containing FPV vaccine further obscures differentiation because this preparation is most likely composed of 2 virus populations that could segregate after immunization of poultry. Moreover, variation in the number of internal, 12 amino acid long, serine-rich repeats that is reflected in the molecular weight of the 39-to 46-kD FPV antigen 1 does not correlate with the degree of virus virulence. For example, both Chick-n-Pox TC and FPV NY-98 strain genomes code for the smallest size of this protein and yet appeared to be as attenuated as the 42-and 46-kD antigen-producing FP VAC strain. 8 In contrast, other field strains (NE-92, CA-98, OK-98), which express only the 39-kD form of this protein, were determined to be very pathogenic for naive chickens. 8 Despite an inability to use these anti-FPV MAbs for predicting biological characteristics of newly isolated FPV, their specificity will be invaluable for epidemiological studies of virus spread and confirmation of diagnoses of fowlpox. The first application addresses the concern that at least some avipox viruses may be capable of infecting more than 1 species of bird. In this regard, viruses genetically and antigenically similar to FPV vaccines have been found in turkeys and also in ostriches. 6 Moreover, the pigeonpox virusbased vaccines may also represent FPV ''cross-overs,'' in this case into pigeons. For instance, there is 100% homology between comparative pigeonpox and fowlpox virus entries in GenBank, and both MAbs used in this study react with similar-sized proteins in both viruses. Thus it appears that these 2 viruses presumably represent 1 virus that has been isolated from 2 different bird species. The second use is directed toward distinguishing between disease caused by FPV and other pathogens that produce similar lesions. For example, infection of the trachea of poultry by ILTV is often confused with the diphtheritic form of fowlpox. In both cases, the MAb-based immuno-dot blot assay described here should allow FPV to be routinely identified on the basis the specific detection of virus antigens in the lesions of infected hosts. Afterwards, further characterization of the FPV strain could be conducted by immunoblotting of the proteins present in such lesions with MAb P1D9.
